1. Generics Bulletin
  2. >>Products

Alkaloids of Australia Slapped With Criminal Cartel Charges

33 Cases Registered Against The Scopolamine N-butylbromide API Supplier

 
• By Akriti Seth

Alkaloids of Australia has been charged with 33 criminal cartel offences for price fixing, market and customer allocation, and bid rigging by the Australian Competition and Consumer Commission. The allegations revolve around scopolamine N-butylbromide. 

Cartel
Australian API company charged with criminal offences for price fixing, market and customer allocation, and bid rigging • Source: Shutterstock

Active pharmaceutical ingredient producer and supplier Alkaloids of Australia Pty Ltd has been charged with 33 criminal cartel offences by local regulatory body, the Australian Competition and Consumer Commission.

The company and its former export manager, Christopher Kenneth Joyce, have been charged with the criminal cartel conduct charges after

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.